Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

Key opportunities in the Global Small Cell Lung Cancer Therapeutics Market include the growing demand for advanced ...

A retrospective study finds that more than one third of patients with stage I-IIIA non-small cell lung cancer do not undergo ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune system better recognize and respond to small cell lung cancer. The study aims to ...

A 25-year study led by the Barcelona Institute for Global Health finds that PM2.5 increases the risk of all lung cancer subtypes, while several gaseous pollutants are associated with non-small-cell ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...